本帖最后由 老马 于 2012-1-13 21:20 编辑
$ m$ p* e4 n, ?; W: ]) ^5 }2 L+ a4 E5 N" j
爱必妥和阿瓦斯丁的比较
" G/ U* }% w" ] C* `2 a& w5 ]
/ q- [2 y5 ^" e8 ^: nhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/0 w( a' _1 v% q, W
; P; K9 _) \0 m8 T" e' a
, E) T. _, B1 q* e& c' C% ^2 h
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/* G/ F5 O$ X+ B+ U
==================================================9 Z! V N& { K y) _% u+ h
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ y) p* I& b% s( |/ Y5 kPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" s/ Q- J1 r+ w& J8 E9 lResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
, O4 h Z) ^0 S w" t3 k
|
显身卡
0 `, H8 u6 S+ B
